WSA
VNDA icon

Wall Street Associates’s Vanda Pharmaceuticals VNDA Stock Holding History

Wall Street Associates’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-655,800
Closed -$9.39M – 352
2014
Q4 		$9.39M Sell
655,800
-7,600
-1% -$89.9K 0.9% 24
2014
Q3 		$6.89M Sell
663,400
-39,300
-6% -$515K 0.71% 46
2014
Q2 		$11.4M Sell
702,700
-2,400
-0.3% -$32K 0.98% 20
2014
Q1 		$11.5M Buy
705,100
+82,800
+13% +$1.18M 0.94% 21
2013
Q4 		$7.72M Buy
622,300
+16,500
+3% +$166K 0.63% 48
2013
Q3 		$6.63M Buy
+605,800
New +$6.47M 0.62% 44

Other funds holding VNDA

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wall Street Associates's VNDA Position: Q1 2015 in Review

Wall Street Associates sold out of Vanda Pharmaceuticals (VNDA) in Q1 2015, closing a stake of 655,800 shares — an estimated $9.39M sold.

Wall Street Associates first reported a position in VNDA in Q3 2013 and held it in 6 quarters. The position peaked at $11.5M in Q1 2014. 110 funds tracked by Wall St. Rank hold VNDA as of Q1 2015.

  • Wall Street Associates reported no remaining Vanda Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Wall Street Associates sold 655,800 Vanda Pharmaceuticals shares in Q1 2015, an estimated $9.39M.
  • Wall Street Associates first reported a position in Vanda Pharmaceuticals in Q3 2013 and held it in 6 quarters.
  • Wall Street Associates's Vanda Pharmaceuticals position peaked at $11.5M in Q1 2014.
  • 110 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2015.

Based on Wall Street Associates's 13F filing for Q1 2015, filed 14 May 2015.